A Double Blind Comparison of Venlafaxine and Paroxetine in Obsessive-Compulsive Disorder

Journal of Clinical Psychopharmacology

Volumn 23, Issue 6, 2003, Pages 568-575

  Denys, Damiaan ^a   Van Der Wee, Nic ^a   Van Megen, Harold J G M ^a   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADULT; APPETITE DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; GASTROINTESTINAL SYMPTOM; HAMILTON SCALE; HEADACHE; HUMAN; LIBIDO DISORDER; MALE; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; SWEATING; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; PATIENT DROPOUTS; PSYCHOLOGICAL TESTS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0344420417     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000095342.32154.54     Document Type: Article

References (29)

1. DeVeaugh-Geiss J, et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group [see comments] Arch Gen Psychiatry. 1991;48:730-738.
2. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996;11:21-29.
3. Tollefson GD, Rampey AH, Jr., Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994;51:559-567.
4. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:57-65.
5. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 1996;169:468-474.
6. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol. 2001;16:75-86.
7. Stein DJ, Spadaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995;10:11-18.
8. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry. 1995;52:53-60.
9. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br J Psychiatry. 1995;166:424-443.
10. Ackerman DL, Greenland S. Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder. J Clin Psychopharmacol. 2002;22:309-317.
11. Roseboom PH, Kalin NH. Neuropharmacology of venlafaxine. Depress Anxiety. 2000;12(Suppl 1):20-29.
12. Harvey AT, Rudolph RL, Preskom SH. Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 2000;57:503-509.
13. Ananth J, Burgoyne K, Smith M, et al. Venlafaxine for treatment of obsessive-compulsive disorder [letter]. Am J Psychiatry. 1995;152:1832.
14. Grossman R, Hollander E. Treatment of obsessive-compulsive disorder with venlafaxine. Am J Psychiatry. 1996;153:576-577.
15. Zajecka JM, Fawcett J, Guy C. Coexisting major depression and obsessive-compulsive disorder treated with venlafaxine. J Clin Psychopharmacol. 1990;10:152-153.
16. Rauch SL, O'Sullivan RL, Jenike MA. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J Clin Psychopharmacol 1996;16:81-84.
17. Yaryura-Tobias JA, Neziroglu FA. Venlafaxine in obsessive-compulsive disorder. Arch Gen Psychiatry. 1996;53:653-654.
18. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-LV and ICD-I0. J Clin Psychiatry. 1998;59(Suppl 20):22-33.
19. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
20. Arntz A, van Beijsterveldt B, Hoekstra R, et al. The interrater reliability of a Dutch version of the Structured Clinical Interview for DSM-III-R Personality Disorders. Acta Psychiatr Scand. 1992;85:394-400
21. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011.
22. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50-55.
23. Toumel G, Houdret N, Hedouin V, et al. High-performance liquid chromatographic method to screen and quantitate seven selective serotonin reuptake inhibitors in human serum. J Chromatogr B Biomed Sci Appl. 2001;761:147-158.
24. McKay D, Danyko S, Neziroglu F, et al. Factor structure of the Yale-Brown Obsessive-Compulsive Scale: a two dimensional measure. Behav Res Ther. 1995;33:865-869.
25. Summerfeldt LJ, Richter MA, Antony MM, et al. Symptom structure in obsessive-compulsive disorder: a confirmatory factor-analytic study. Behav Res Ther. 1999;37:297-311.
26. Rudolph RL, Derivan AT. The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database. J Clin Psychopharmacol. 1996;16:54S-59S.
27. Porter RJ, McAllister-Williams RH, Young AH. Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychopharmacology (Berl). 1999;146:194-198.
28. Austin LS, Lydiard RB, Ballenger JC, et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;30:225-232.
29. Greist J, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995;52:289-295.